Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Terminated × Pluvicto × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2 1 Phase 1/2 1

Status

Recruiting 13 Active not recruiting 7 Not yet recruiting 2 Completed 2 Unknown 1 Terminated 1 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration Resistant Prostate Cancer 1

Interventions

Cyclophosphamide 166 Docetaxel 153 Bevacizumab 153 Gemcitabine 144 Carboplatin 144 Cisplatin 142 pembrolizumab 140 Radiotherapy 134 Paclitaxel 129 Capecitabine 121 Rituximab 115 Oxaliplatin 103 Fluorouracil 102 Nivolumab 90 Irinotecan 85 Doxorubicin 85 Leucovorin 81 Dexamethasone 81 Pemetrexed 79 fludarabine 74 fludarabine phosphate 72 Bortezomib 68 Etoposide 66 Erlotinib Hydrochloride 66 Cetuximab 64 Methotrexate 58 Trastuzumab 56 Cytarabine 54 Lenalidomide 49 Everolimus 49

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03042312 2021-03-24

RESIST-PC

Endocyte

Phase 2 Terminated

71 enrolled 15 charts

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡